Ysios Capital Overview

  • Investor Type
  • Venture Capital

  • Status
  • Active

  • Professionals
  • 11

Professionals
  • Investments
  • 61

  • Portfolio
  • 23

  • Exits
  • 16

Exits

Ysios Capital General Information

Description

Founded in 2008, Ysios Capital is a venture capital investment firm based in San Sebastián, Spain. The firm seeks to invest in early and mid-stage companies operating in biotech, human healthcare, life science and focuses exclusively on innovative therapeutic drugs companies.

Contact Information

Year Founded
2008
Investor Status
Actively Seeking New Investments
Trade Association
Spanish Venture Capital Association (ASCRI)
Principles for Responsible Investment (PRI)
Primary Investor Type
Venture Capital
Primary Office
  • Avenida de la Libertad
  • 25, 4th floor
  • 20004 San Sebastian
  • Spain
+34 943 00 00 00

Ysios Capital Investments (61)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Mineralys 08-Jun-2022 Early Stage VC 00000 Drug Discovery Generating Revenue
0000000 31-May-2022 00000 00000 000.00 Drug Discovery Generating Revenue 00000 000000 00.0
000000 000 16-Feb-2022 00000 00000 000.00 Drug Discovery Generating Revenue 00ë0 0000-000000 00.0
00000000 000000000 17-Dec-2021 00000 00000 0000 Drug Discovery Clinical Trials - Phase 2 00000 0000 00.0
000000 000000 04-May-2021 00000 00000 0000 Drug Discovery Clinical Trials - Phase 1 00000 000000 00.0
0000000 29-Apr-2021 00000 00000 000.00 Biotechnology Pre-Clinical Trials 00ë0 0000-000000 00.0
00000000 000000000 20-Apr-2021 00000 00000 000.00 Drug Discovery Clinical Trials - General 00ú0 0000í0-0000 00.0
0000 00000000000 22-Mar-2021 00000 00000 0000 Drug Discovery Generating Revenue 00ë0 0000-000000 00.0
Corwave 06-Jan-2021 Later Stage VC 000.00 Surgical Devices Generating Revenue 00ú0 0000í0-0000 00.0
SparingVision 21-Oct-2020 Later Stage VC 000.00 Drug Discovery Generating Revenue 00000 000000 00.0
You’re viewing 10 of 61 investments. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ysios Capital Exits (16)

Company Name Exit Date Exit Type Exit Size
Aura Biosciences 02-Nov-2021 IPO 000.00
0000 30-Jun-2021 000 00000
0000 000000000000 25-Mar-2021 000 00000
0000000 0000000000 04-Mar-2021 000 00 00000000
0000000 29-Oct-2020 000 0000
00000000000 01-Sep-2018 000 00 00000000
0000-00 19-Apr-2018 000000000000000000 00000
0000000 0000000000 16-Mar-2018 000000000000000000 00000
TiGenix 04-Jan-2018 Merger/Acquisition 00000
Kala Pharmaceuticals 20-Jul-2017 IPO 0000
You’re viewing 10 of 16 exits. Get the full list »

Ysios Capital Fund Performance

Fund Name Vintage Size Dry Powder DPI RVPI TVPI IRR

This information is available in the PitchBook Platform. To explore Ysios Capital‘s full profile, request access.

Request a free trial

Ysios Capital Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Ysios Capital Team (28)

Name Title Deals Funds Boards Office
Iñigo López-Huerta Finance Director & Chief Financial Officer San Sebastian, Spain
Joël Jean-Mairet Ph.D Co-Founder & Managing Partner 00 0 0 Barcelona, Spain
Julia Salaverría Co-Founder & Managing Partner 0 0 San Sebastian, Spain
Karen Wagner Ph.D Managing Partner 00 0 0 Zurich, Switzerland
Cristina Garmendia Mendizábal Ph.D General Partner & Co-Founding Partner Barcelona, Spain
You’re viewing 5 of 28 team members. Get the full list »

Ysios Capital Co-Investors (110)

Name With Exits Lead Partner Series Industry
Gilde Healthcare Partners 5 0 0 Series chart Industry bar
Novo Holdings 0 0 Series chart Industry bar
Caixa Capital Risc 0 0 0 Series chart Industry bar
EQT Life Sciences 0 0 0 Series chart Industry bar
Kurma Partners 0 0 Series chart Industry bar
You’re viewing 5 of 110 co-investors. Get the full list »